keyword
MENU ▼
Read by QxMD icon Read
search

Non alcoholic steatohepatitis

keyword
https://www.readbyqxmd.com/read/29662454/the-biological-clock-a-pivotal-hub-in-non-alcoholic-fatty-liver-disease-pathogenesis
#1
REVIEW
Gianluigi Mazzoccoli, Salvatore De Cosmo, Tommaso Mazza
Non-alcoholic fatty liver disease (NAFLD) is the most frequent hepatic pathology in the Western world and may evolve into steatohepatitis (NASH), increasing the risk of cirrhosis, portal hypertension and hepatocellular carcinoma. NAFLD derives from the accumulation of hepatic fat due to discrepant free fatty acid metabolism. Other factors contributing to this are deranged nutrients and bile acids fluxes as well as alterations in nuclear receptors, hormones, and intermediary metabolites, which impact on signaling pathways involved in metabolism and inflammation...
2018: Frontiers in Physiology
https://www.readbyqxmd.com/read/29660603/both-alcoholic-and-non-alcoholic-steatohepatitis-association-with-cardiovascular-risk-and-liver-fibrosis
#2
Beatriz A Sánchez-Jiménez, Diana Brizuela-Alcántara, Martha H Ramos-Ostos, Luis F Alva-López, Misael Uribe-Esquivel, Norberto C Chávez-Tapia
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide. Mortality in NAFLD is mainly related to cardiovascular disease (CVD) and cancer. NAFLD and its association with both CVD and liver disease risk have been well evaluated, but the association of NAFLD with alcohol, known as "both alcoholic and non-alcoholic steatohepatitis" (BASH), remains uncertain. The objective of this study was to assess the influence of alcohol and obesity in the development of liver and cardiovascular disease risk...
November 15, 2017: Alcohol
https://www.readbyqxmd.com/read/29656250/exposure-to-environmental-level-phenanthrene-induces-a-nash-like-phenotype-in-new-born-rat
#3
Jiaojiao Guo, Chonggang Wang, Zhizhun Guo, Zhenghong Zuo
More and more evidence indicates that persistent organic pollutants (POPs) are a risk factor for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Phenanthrene (Phe) is a kind of POP which existed extensively in the environment, but whose toxicity on mammals has so far received less focus. Subcutaneously injection of Phe (0.5, 5, 50 μg/kg) for 21 days induced significant NAFLD/NASH symptoms in new born rats. Exposure to environmental levels of Phe decreased body weight and liver-somatic index; impaired histology of liver; influenced the peroxisome proliferator-activated receptor gamma (PPARγ) signaling and lipid metabolism in liver; stimulated oxidative stress in the rats' liver; induced the variation of NFκB pathway and liver inflammatory response; and caused liver fibrosis via transforming growth factor β1 (tgfβ1)...
April 12, 2018: Environmental Pollution
https://www.readbyqxmd.com/read/29627620/efficacy-safety-and-tolerability-of-lubiprostone-for-the-treatment-of-non-alcoholic-fatty-liver-disease-in-adult-patients-with-constipation-the-lubiprone-double-blind-randomised-placebo-controlled-study-design
#4
Takaomi Kessoku, Kento Imajo, Takashi Kobayashi, Yasushi Honda, Takayuki Kato, Yuji Ogawa, Wataru Tomeno, Shingo Kato, Takuma Higurashi, Masato Yoneda, Hiroyuki Kirikoshi, Kazuki Kubota, Masataka Taguri, Takeharu Yamanaka, Haruki Usuda, Koichiro Wada, Satoru Saito, Atsushi Nakajima
BACKGROUND: This paper reports the protocol of a randomised, double-blind, placebo-controlled study to test the efficacy, safety, and tolerability of lubiprostone (LUB) vs. placebo on suppressing gut permeability in non-alcoholic fatty liver disease (NAFLD) patients with constipation. NAFLD, including non-alcoholic steatohepatitis (NASH), is a common chronic liver disorder. Progression is associated with increased gut permeability and gut-derived endotoxins. Most NAFLD/NASH clinical trial drugs aim to improve liver function or systemic metabolism...
April 5, 2018: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/29611411/erratum-to-pathologic-impact-of-insulin-resistance-and-sensitivity-on-the-severity-of-liver-histopathology-in-pediatric-non-alcoholic-steatohepatitis-by-park-bh-et-al-yonsei-med-j-2017-58-756-762
#5
https://www.readbyqxmd.com/read/29608898/canagliflozin-protects-against-non-alcoholic-steatohepatitis-in-type-2-diabetic-rats-through-zinc-alpha-2-glycoprotein-up-regulation
#6
Soad L Kabil, Nevertyty M Mahmoud
Elevated blood glucose and insulin resistance are triggering factors for non-alcoholic steatohepatitis (NASH). We investigated the effects of the Sodium Glucose co-Transporter 2 (SGLT2) inhibitor canagliflozin on NASH development in rats with type 2 diabetes mellitus as well as the possible underlying mechanisms and for the first time the effect of canagliflozin on the hepatic zinc-α2-glycoprotein (ZAG) levels. Rats were treated with nicotinamide and streptozotocin to reduce the insulin secretory capacity then fed high fat diet for 8 weeks...
March 30, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29607530/systematic-review-drug-induced-liver-injury-alternative-causes-in-case-series-as-confounding-variables
#7
REVIEW
Rolf Teschke, Gaby Danan
AIMS: Drug-induced liver injury (DILI) is rare as compared to the worldwide frequent acute or chronic liver diseases. Therefore, patients included in series of suspected DILI are at high risk of not having DILI, whereby alternative causes may confound the DILI diagnosis. The aim of this review is to evaluate published case series of DILI for alternative causes. METHODS: Pertinent studies were identified using a computerized search of the Medline database for publications from 1993 through 30 October 2017...
April 1, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29603380/identification-of-chromatin-accessible-domains-in-non-alcoholic-steatohepatitis-derived-hepatocellular-carcinoma
#8
Mekonnen Lemma Dechassa, Volodymyr Tryndyak, Aline de Conti, Wenming Xiao, Frederick A Beland, Igor P Pogribny
Non-alcoholic steatohepatitis (NASH) is becoming one of the major causes of hepatocellular carcinoma (HCC) in the United States and Western countries; however, the molecular mechanisms associated with NASH-related liver carcinogenesis are not well understood. In the present study, we investigated cancer-associated chromatin alterations using a model that resembles the development of NASH-related HCC in humans. An assay for transposase-accessible chromatin with high throughput sequencing (ATAC-seq) identified 1,677 tumor-specific chromatin-accessible regions in NASH-derived HCC tissue samples...
March 30, 2018: Molecular Carcinogenesis
https://www.readbyqxmd.com/read/29602237/nefa-induced-ros-impaired-insulin-signalling-through-the-jnk-and-p38mapk-pathways-in-non-alcoholic-steatohepatitis
#9
Wenwen Gao, Xiliang Du, Lin Lei, Heyuan Wang, Min Zhang, Zhe Wang, Xiaobing Li, Guowen Liu, Xinwei Li
The aim of this study was to investigate the changes in hepatic oxidative phosphorylation (OXPHOS) complexes (COs) in patients and cows with non-alcoholic steatohepatitis (NASH) and to investigate the mechanism that links mitochondrial dysfunction and hepatic insulin resistance induced by non-esterified fatty acids (NEFAs). Patients and cows with NASH displayed high blood NEFAs, TNF-α and IL-6 concentrations, mitochondrial dysfunction and insulin resistance. The protein levels of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), mitofusin-2 (Mfn-2) and OXPHOS complexes (human: COI and COIII; cow: COI-IV) were significantly decreased in patients and cows with NASH...
March 30, 2018: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/29600430/targeting-incretin-hormones-and-the-ask-1-pathway-as-therapeutic-options-in-the-treatment-of-non-alcoholic-steatohepatitis
#10
REVIEW
Alexander J Kovalic, Sanjaya K Satapathy, Naga Chalasani
Non-alcoholic fatty liver disease (NAFLD) is currently one of the leading forms of chronic liver disease, and its rising frequency worldwide has reached epidemic proportions. NAFLD, particularly its progressive variant NASH (non-alcoholic steatohepatitis), can lead to advanced fibrosis, cirrhosis, and HCC. The pathophysiologic mechanisms that contribute to the development and progression of NAFLD and NASH are complex, and as such myriad therapies are under investigation targeting different pathophysiological mechanisms...
March 29, 2018: Hepatology International
https://www.readbyqxmd.com/read/29598814/editorial-non-alcoholic-fatty-liver-disease-and-non-alcoholic-steatohepatitis-an-epidemic-that-will-boost-the-incidence-of-cardiovascular-morbidity-and-mortality
#11
EDITORIAL
Vasilios G Athyros, Michael Doumas
No abstract text is available yet for this article.
2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29597210/euodia-daniellii-hemsl-bee-bee-tree-oil-attenuates-palmitate-induced-lipid-accumulation-and-apoptosis-in-hepatocytes
#12
Tae Woo Jung, Sun-Young Kim, Da-Som Kim, Eui-Cheol Shin, Yong Bae Park, Kyoung-Tae Lee
Hepatic lipid accumulation and apoptosis is elevated in patients with non-alcoholic steatohepatitis and is closely associated with severity. Saturated fatty acid palmitate stimulates lipid accumulation and apoptosis in hepatocytes. In the present study, we examined bee-bee tree oil (BO)-mediated protective effects on palmitate-induced lipid accumulation and apoptosis in mouse primary hepatocytes. Cells were cultured in a control media or the same media containing 150 or 300 µmol/L of albumin-bound palmitate for 24 h...
March 29, 2018: Pharmacology
https://www.readbyqxmd.com/read/29590379/increased-plasma-proneurotensin-levels-identify-nafld-in-adults-with-and-without-type-2-diabetes
#13
Ilaria Barchetta, Flavia Agata Cimini, Frida Leonetti, Danila Capoccia, Claudio Di Cristofano, Gianfranco Silecchia, Marju Orho-Melander, Olle Melander, Maria Gisella Cavallo
Context: Neurotensin (NT) is an intestinal peptide released by fat ingestion and promoting lipids absorption; higher circulating NT levels associate with type 2 diabetes (T2D), obesity and cardiovascular disease. Whether NT is related to non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) has not been fully investigated. Objective: To study the relationship between plasma proneurotensin1-117 (pro-NT), a stable fragment of the NT precursor hormone, and the presence/severity of NAFLD/NASH and to unravel correlates of increased pro-NT levels...
March 23, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29580767/fatty-liver-index-is-associated-to-pulse-wave-velocity-in-healthy-subjects-data-from-the-brisighella-heart-study
#14
Arrigo F G Cicero, Stefano Gitto, Federica Fogacci, Martina Rosticci, Marina Giovannini, Sergio D'Addato, Pietro Andreone, Claudio Borghi
BACKGROUND: Non-Alcoholic Fatty Liver Disease (NAFLD) is associated to increased risk of cardiovascular disease. Our aim was to evaluate association of indexes of fatty liver with arterial stiffness (AS). METHODS: We analyzed data of adult volunteers visited during the last Brisighella survey. We evaluated the Pulse Wave Velocity (PWV) and the following non-invasive indexes of liver steatosis: Fatty Liver Index (FLI), Lipid Accumulation Product (LAP), Hepatic Steatosis Index (HSI)...
March 23, 2018: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29574534/to-die-or-not-to-die-death-signaling-in-nonalcoholic-fatty-liver-disease
#15
REVIEW
Yuko Akazawa, Kazuhiko Nakao
Non-alcoholic fatty liver disease (NAFLD) is an emerging liver disease worldwide. In subset of patients, NAFLD progresses to its advanced form, nonalcoholic steatohepatitis (NASH), which is accompanied with inflammation and fibrosis. Saturated free fatty acid-induced hepatocyte apoptosis is a feature of NASH. Death signaling in NASH does not always result in apoptosis, but can alternatively lead to the survival of cells presenting signs of pro-inflammatory and pro-fibrotic signals. With the current lack of established treatments for NASH, it is important to understand the molecular mechanisms responsible for disease development and progression...
March 24, 2018: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29573551/case-report-of-high-dose-hydroxocobalamin-in-the-treatment-of-vasoplegic-syndrome-during-liver-transplantation
#16
S Sandy An, C Patrick Henson, Robert E Freundlich, Matthew D McEvoy
A 66-year-old male with cryptogenic cirrhosis secondary to non-alcoholic steatohepatitis (NASH) presented for orthotopic liver transplantation. Following organ reperfusion, the patient developed vasoplegic syndrome, with arterial blood pressures of approximately 60-70/30-40 mmHg (mean arterial pressure, MAP<45 mmHg) for over 90 minutes. He required high-dose norepinephrine and vasopressin infusions, as well as intravenous bolus doses of norepinephrine and vasopressin to reach a goal MAP> 60 mmHg. There was minimal response to a 2 mg/kg intravenous (IV) bolus of methylene blue...
March 24, 2018: American Journal of Transplantation
https://www.readbyqxmd.com/read/29572095/a-simple-diet-and-chemical-induced-murine-nash-model-with-rapid-progression-of-steatohepatitis-fibrosis-and-liver-cancer
#17
Takuma Tsuchida, Youngmin A Lee, Naoto Fujiwara, Maria Ybanez, Brittany Allen, Sebastiao Martins, M Isabel Fiel, Nicolas Goossens, Hsin-I Chou, Yujin Hoshida, Scott L Friedman
BACKGROUND AND AIMS: Although the majority of patients with nonalcoholic fatty liver disease (NAFLD) have only steatosis without progression, a sizable fraction develop non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and hepatocellular carcinoma (HCC). Many established diet-induced mouse models for NASH require 24-52 weeks, which makes testing for drug response costly and time consuming. METHODS: We have sought to establish a murine NASH model with rapid progression of extensive fibrosis and HCC by using a western diet (WD), which is high-fat, high-fructose and high-cholesterol, combined with low dose weekly intraperitoneal carbon tetrachloride (CCl4 ), which served as an accelerator...
March 20, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29564203/simultaneous-liver-kidney-transplantation-impact-on-liver-transplant-patients-and-the-kidney-transplant-waiting-list
#18
REVIEW
Clifford D Miles, Scott Westphal, AnnMarie Liapakis, Richard Formica
Purpose: The number of simultaneous liver-kidney transplants (SLKT) performed in the USA has been rising. The Organ Procurement and Transplantation Network implemented a new policy governing SLKT that specifies eligibility criteria for candidates to receive a kidney with a liver, and creates a kidney waitlist "safety net" for liver recipients with persistent renal failure after transplant. This review explores potential impacts for liver patients and the kidney waitlist. Recent Findings: Factors that have contributed to the rise in SLKT including Model for End-stage Liver Disease (MELD)-based allocation, regional sharing for high MELD candidates, and the rising incidence of non-alcoholic steatohepatitis will continue to increase the number of liver transplant candidates with concurrent renal insufficiency...
2018: Current Transplantation Reports
https://www.readbyqxmd.com/read/29564059/is-treatment-of-fatty-liver-effective-on-reducing-carotid-intima-media-thickness-a-cohort-study
#19
Saeideh Ghaffarifar, Manouchehr Khoshbaten, Fattaneh Dordaei, Maryam Zareh Nahandi, Reza Javad-Rashid, Tahereh Shahnazi
Aim: This study was intended to explore the effect of various drugs used to treat fatty liver on intimal-media thickness in patients with NAFLD. Background: Nonalcoholic fatty liver disease (NAFLD) is an indicator of a broad spectrum of pathologic disorders, which is characterized with macro vesicular steatosis in the absent of alcohol use. It has a wide range of laboratory, clinical and pathological presentations such as simple steatosis to the diseases like non-alcoholic steatohepatitis, fibrosis, and cirrhosis and hepatocellular cancer...
2018: Gastroenterology and Hepatology From Bed to Bench
https://www.readbyqxmd.com/read/29560647/hepatic-complications-of-bariatric-surgery-the-reverse-side-of-the-coin
#20
REVIEW
U Vespasiani-Gentilucci, F Vorini, S Carotti, A De Vincentis, G Galati, P Gallo, N Scopinaro, A Picardi
BACKGROUND: Even if the jejunoileal bypass has been definitely abandoned due to the high rate of hepatic complications, cases of liver injury after the new bariatric procedures are still reported. We aimed to review the available literature concerning liver damage associated with the older and newer types of bariatric surgeries. METHODS: An extensive literature search of MEDLINE was performed using different combinations of the following terms: "bariatric surgery OR biliopancreatic diversion OR jejunoileal bypass OR roux-en-y gastric bypass OR vertical banded gastroplasty OR laparoscopic adjustable gastric banding" AND "hepatic/liver damage OR hepatic/liver impairment OR hepatic/liver failure"...
October 2017: Acta Gastro-enterologica Belgica
keyword
keyword
41965
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"